Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
Unlike fleeting sugar hits, protein keeps hunger in check, stabilizes energy levels and supports lean muscle a perfect match for the new landscape where shoppers want fewer calories but more staying power
reduced sensitivity after stress or hormonal changes
Semaglutide is prescribed as a once-weekly injection, so every 10 days isnt a standard dosing schedule
Its FDA-approved for diabetes and its potential weight-loss effects are currently being studied (7)
CaMKK2 as an emerging treatment target for bipolar disorder
